PDZK1 Upregulation in Estrogen-Related Hyperpigmentation in Melasma  by Kim, Nan-Hyung et al.
PDZK1 Upregulation in Estrogen-Related
Hyperpigmentation in Melasma
Nan-Hyung Kim1, Kyung Ah Cheong1, Tae Ryong Lee2 and Ai-Young Lee1
The pathogenesis of melasma is unknown, although the potential role of estrogen has been considered.
Microarray and real-time PCR analyses revealed that upregulation of PDZ domain protein kidney 1 (PDZK1) is
clinically correlated with melasma. Although there has been no report that PDZK1 is involved in pigmentation
and/or melanogenesis, PDZK1 expression can be induced by estrogen. In this study, the role of PDZK1
upregulation in melasma was examined, particularly in connection with estrogen, using biopsied skin
specimens from 15 patients and monocultures and cocultures of melanocytes and keratinocytes with or without
overexpression or knockdown of PDZK1. Estrogen upregulated PDZK1. Overexpression of PDZK1 increased
tyrosinase expression and melanosome transfer to keratinocytes, whereas PDZK1 knockdown reduced
estrogen-induced tyrosinase expression, through regulation of expression of estrogen receptors (ERs) ER-a and
ER-b. The PDZK1-induced tyrosinase expression and melanosome transfer was regulated by ion transporters
such as sodium–hydrogen exchanger (NHE), cystic fibrosis transmembrane conductance regulator (CFTR), and
SLC26A3, which showed a specific association with each ER subtype. In the melanosome transfer, PDZK1 also
increased phosphorylation of ezrin/radixin/moesin (ERM) and ras-related C3 botulinum toxin substrate 1, but
not the expression of proteinase-activated receptor-2. Collectively, upregulation of PDZK1 could have an
important role in the development of melasma in connection with estrogen through NHE, CFTR, and SLC26A3.
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INTRODUCTION
Melasma refers to a pattern of hyperpigmentation that affects
skin on the upper lip, cheeks, forehead, and chin, particularly
during the reproductive lifespan of women. Melasma differs
from post-inflammatory hyperpigmentation and UV-induced
pigmentation in that it persists and is difficult to treat. As a
variety of factors, including pregnancy and changes in uterine
and ovarian hormones, have been implicated in the pathogen-
esis of melasma, the role(s) of estrogen and/or progesterone has
been considered. In fact, immunohistochemical staining has
shown an increased estrogen receptor (ER) expression in
affected compared with unaffected skin (Lieberman and Moy,
2008; Jang et al., 2010). However, it is uncertain as to what
role estrogen has in melasma. Recently, microarray analysis to
compare hyperpigmented to normally pigmented skin from
patients with melasma was performed to identify specific
factors associated with the hyperpigmentation. There was a
2-fold or greater upregulation in the expression of PDZ domain
protein kidney 1 (PDZK1) in the hyperpigmented skin of
melasma patients (data not shown). PDZK1 is a member of the
sodium–hydrogen exchanger regulatory factor (NHERF) family,
called NHERF-3. NHERF-1 and NHERF-2 contain two PDZ
domains, whereas NHERF-3 and NHERF-4 each have four
PDZ domains, which mediate the most abundant protein–
protein interactions. Studies have been rarely conducted for
NHERF-3 and NHERF-4. NHERF proteins have not been
investigated in the skin, nor has the involvement of PDZK1 in
skin pigmentation. However, NHERF-1 has been identified as
an estrogen-regulated gene in ER-containing breast cancer
cells (Ediger et al., 1999). PDZK1 expression can also be
induced by estrogen (Ghosh et al., 2000).
In the regulation of ion transport in a variety of epithelia,
including the kidney, intestine, pancreas, and the airway,
NHERF proteins have been shown to bind to NHE, cystic
fibrosis transmembrane conductance regulator (CFTR), and
the SLC26A family. Mammalian NHE is an integral mem-
brane protein that functions to exchange one intracellular
Hþ for one extracellular Naþ (Nakamura et al., 2005).
The NHE1 of nine isoforms is ubiquitously expressed in
the plasma membrane of virtually all tissues, whereas the
NHE2–NHE5 isoforms have more restricted tissue distribu-
tions. In the skin, NHE1 has been identified in cultured
keratinocytes and melanocytes (Sarangarajan et al., 2001;
Smith et al., 2004), and NHE3 has been identified in
melanocytes (Sarangarajan et al., 2001). As NHE3 predomi-
nantly mediates electroneutral sodium absorption, which
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takes up Cl with Naþ in a one-to-one ratio, it may be a
prerequisite to be coupled to one or several isoforms of the
SLC26 apical anion exchanger family (Mount and Romero,
2004). The interaction of both transporters may augment pH-
mediated regulation (Lamprecht and Seidler, 2006). The
reciprocal activation of transport function has identified an
interaction between SLC26 and CFTR. In fact, CFTR is
localized in the apical membrane of epithelial cells and
functions as a Cl channel and regulates Cl and HCO3

secretion (Grubb and Boucher, 1999), particularly in con-
junction with SLC26 anion transporters (Ko et al., 2004; Singh
et al., 2010). In normal human skin, CFTR expression has
been examined in epidermal keratinocytes, as well as in
eccrine sweat glands and ducts (Sato et al., 2002), but not in
melanocytes.
So far, there has been no evidence to implicate PDZK1, as
well as NHE3, CFTR, and SLC26, in melasma. Although
PDZK1 can be induced by estrogen (Ghosh et al., 2000), no
study on the expression or function of NHERF proteins,
including PDZK1, has been conducted on the skin. Never-
theless, a broad role of the NHERF family in the organization
of signaling complexes and control of cell physiology has
been suggested with rapid increase in the identified
intracellular targets. In this study, we report that PDZK1
upregulation is involved in hyperpigmentation of melasma,
which resulted from an increase in melanogenesis and
melanosome transfer to keratinocytes, and is associated with
estrogen responses through ion transporters, such as NHE3,
CFTR, and SLC26A3.
RESULTS
Upregulation of PDZK1 in hyperpigmented compared with
normally pigmented skin of patients with melasma increases
tyrosinase expression
Levels of PDZK1 mRNA expression were measured using
real-time PCR and were compared between hyperpigmented
and normally pigmented skin specimens biopsied from 15
patients with melasma. The level of PDZK1 mRNA was
higher in hyperpigmented than in normally pigmented skin,
showing a statistical significance (P¼ 0.015; Figure 1a).
Immunohistochemical staining with an anti-PDZK1 antibody
showed stronger reactivity with the hyperpigmented com-
pared with the normally pigmented epidermis (Figure 1b). In
the epidermis, not only keratinocytes but also melanocytes
were PDZK1 positive (Figure 1b).
Before overexpressing PDZK1 in skin cells, the expression
levels of PDZK1 were examined in three different populations
of cultured normal human melanocytes and keratinocytes.
Keratinocytes showed uniformly high levels of PDZK1
expression, whereas melanocytes had lower levels of PDZK1
expression with intercellular variation compared with the
keratinocytes (Figure 1c). Overexpression of PDZK1 in
melanocytes increased expression levels of tyrosinase, which
was also examined in cocultures with overexpression in only
keratinocytes or in keratinocytes and melanocytes (Figure 1d).
PDZK1 overexpression in monocultures and/or in cocultures
increased the phosphorylation of extracellular signal–regulated
kinase, CRE-binding protein, and protein kinase C, as well as
the expression of microphthalmia-associated transcription
factor (Figure 1e).
PDZK1 affects estrogen-induced tyrosinase expression through
the regulation of ER expression
Estrogen has been known to stimulate the production of
NHERF in ER–containing cells (Ediger et al., 1999; Stemmer-
Rachamimov et al., 2001). Although NHERFs have not been
reported in keratinocytes or melanocytes despite the presence
of ERs in those cells, treatment of melanocyte monocultures
and melanocyte–keratinocyte cocultures with estrogen
upregulated PDZK1 and tyrosinase expression (Figure 2a).
Overexpression of PDZK1 further increased estrogen-stimu-
lated tyrosinase expression, whereas knockdown of PDZK1
more than 60% at the mRNA level and 37% at the protein
level using a mixture of two different stealth small interfering
RNAs reduced tyrosinase expression to the level of the
untreated control (Figure 2b). As estrogen is known to exert
biological effects that are mediated by two distinct ERs, ER-a
and ER-b (Katzenellenbogen et al., 2000), the effect of PDZK1
on the expression of ERs was examined. The overexpression
of PDZK1 significantly (Po0.05) increased both ER-a and ER-
b expression (Figure 2c), whereas the knockdown of PDZK1
eliminated estrogen-induced expression of both ERs (Figure
2d). At least one ER subtype was significantly upregulated
in the hyperpigmented skin compared with the normally
pigmented skin of 14 melasma patients, in which ER
expression of the 15 patients with PDZK1 upregulation could
be measured (Figure 2e).
PDZK1 over-expression upregulates NHE, CFTR, and SLC26A3
As PDZK1 contains four protein–protein interacting PDZ
domains, known ion transporters, such as NHE, CFTR, and
SLC26, were examined after overexpression of PDZK1 in
melanocyte monocultures and in melanocyte–keratinocyte
cocultures. In the case of NHE, the expression of NHE1 and
NHE3, which have been detected in cultured keratinocytes
and melanocytes (Sarangarajan et al., 2001; Behne et al.,
2002; Smith et al., 2004), was examined. Overexpression of
PDZK1 in either type of monoculture or coculture signifi-
cantly (Po0.05) increased protein levels of all those
molecules compared with the untreated controls (Figure 3a).
Immunoprecipitation using an anti-PDZK1 antibody showed
an increased binding between PDZK1 and those ion
transporters both in keratinocytes and melanocytes following
the PDZK1 overexpression (Figure 3b). Immunohistochemistry
showed that upregulation of PDZK1 increased the staining
intensity for those molecules including CFTR, with the
colocalization of PDZK1 and ion transporters both in
melanocytes and keratinocytes (CFTR shown in Figure 3c,
data from other molecules not shown).
NHE3, CFTR, and SLC26A3 are involved in estrogen-related
tyrosinase expression
The results shown above demonstrate that PDZK1 has a role
in estrogen-induced tyrosinase expression through ERs
(Figure 2a–e). As PDZK1 interacts with CFTR, NHE3, and
SLC26 in melanocytes in the presence or absence of
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keratinocytes (Figure 3a–c), the interaction of PDZK1 with
NHE3, CFTR, and SLC26A3 in estrogen-induced tyrosinase
expression was examined. The expression of those transporter
proteins increased with the concentration of estrogen (Figure
4a). The estrogen-induced upregulation of tyrosinase in the
presence or absence of PDZK1 was significantly (Po0.05)
inhibited by 5-ethylisopropyl amiloride and the CFTR
Inhibitor-172 (3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxy-
phenyl)methylene]-2-thioxo-4-thiazolidinone), specific inhi-
bitors of NHE3 (Figure 4b) and CFTR (Figure 4c), respectively,
without any change in PDZK1 expression. The association of
the ion transporter with ER subtypes was also examined using
specific agonists of ER-a (propyl pyrazoletriol) and ER-b
(diarylpropionitrile). Treatment with propyl pyrazoletriol
significantly (Po0.05) increased the expression of NHE3
along with ER-a, without any change in ER-b or CFTR
expression. On the other hand, treatment with diarylpropio-
nitrile significantly (Po0.05) increased CFTR expression
without any change of NHE3 levels (Figure 4d). The
relationship between each ER subtype and NHE3 or CFTR
expression was also examined in skin specimens from 12 of
the 15 melasma patients with PDZK1 upregulation. A parallel
increased and decreased expression between NHE3 and ER-a
was detected in 5 and 2 of the 12 patients, respectively. In the
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Figure 1. Increased PDZK1 expression in hyperpigmented skin of melasma patients increases tyrosinase expression. (a) Real-time PCR results for relative
ratios of PDZ domain protein kidney 1 (PDZK1) mRNA expression in hyperpigmented (L) compared with normally pigmented (N) skin biopsied from 15 patients.
(b) Immunohistochemical staining with anti-PDZK1 and anti-c-Kit antibodies. Nuclei were counterstained with Hoechst 33258 (bar¼0.1mm). (c) Reverse
transcription–PCR analysis of PDZK1 expression in cultured normal human melanocytes (MC) and keratinocytes (KC). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal standard. (d, e) Western blot analysis of PDZK1, tyrosinase, extracellular signal–regulated kinase (ERK), CRE-
binding protein (CREB), protein kinase C (PKC), and microphthalmia-associated transcription factor (MITF) expression in monocultures of keratinocytes or
melanocytes and in mixed cell cultures (KCþMC) 24hours after the transfection with either PDZK1 (PDZK1) or control vector (C). Data in the graphs represent
means±SD of five independent experiments (*Po0.05).
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case of CFTR, which was measured in 12 patients, 7 and 3
patients showed a parallel increase and decrease with ER-b,
respectively (Figure 4e).
PDZK1 and ion transporter are involved in estrogen-induced
melanosome transfer
Considering the important role of melanosome transfer to
neighboring keratinocytes in skin pigmentation, the effect of
PDZK1 upregulation on melanosome transfer was examined
in a melanocyte–keratinocyte coculture system. FACS analy-
sis using TYRP-1 and K14 antibodies showed that over-
expression of PDZK1 significantly (Po0.05) increased the
proportion of TYRP-1 and K14 double-positive cells, whereas
specific inhibitor of ERs, NHE3, and CFTR reduced PDZK1-
stimulated melanosome transfer to the level of the untreated
control (Figure 5a). In the melanosome transfer, the role of
proteinase-activated receptor (PAR)2 has been identified
(Seiberg et al., 2002). In addition, ras-related C3 botulinum
toxin substrate 1 (Rac1) is known to be involved in dendrite
formation (Scott and Cassidy, 1998). The involvement of
ezrin/radixin/moesin (ERM) in melanosome transfer might be
expected from the effect of stem cell factor on melanocyte
dendricity (Grichnik et al., 1998) and the role of ERM
phosphorylation on the stem cell factor–induced action on
melanocytes (Jeon et al., 2009). Therefore, western blot
assays for ERM, Rac1, and PAR2 were performed, which
showed a significant (Po0.05) increase of ERM and Rac1
phosphorylation, but not PAR-2 expression (Figure 5b).
DISCUSSION
Our quantitative real-time PCR analysis identified a clinical
correlation between the upregulation of PDZK1 and melasma
(Figure 1a), although the correlation was not analyzed
according to individual variables, such as age of patients,
disease duration, sun exposure, and serum levels of estrogen.
PDZK1 could be associated with NHERF1 (Gisler et al., 2003;
Broere et al., 2009); however, there was no significant
upregulation of NHERF-1 in the same patients (data not
shown). Immunohistochemistry of melasma skin and western
blotting analysis of cultured cells showed that both keratino-
cytes and melanocytes were sources of PDZK1 expression
in the epidermis (Figure 1b and c), which supported the
Tyrosinase
Tyrosinase
PDZK1
KC+MC
Estrogen 0 10 100 (nM)
Estrogen 0 10 100
0 10 100 0 10 100 (nM)
0 10 100 0 10 100 (nM)
0 10 100 (nM)
MC KC+MC
KC+MC
KC+MC
PDZK1
b
*
*
*
R
el
at
iv
e
 r
a
tio
 o
f 
ty
ro
sin
as
e/
ac
tin
Fold
3
R
el
at
iv
e 
ra
tio
 o
f P
DZ
K1
 
 
m
R
N
A 
ex
pr
es
sio
n 
*
*
MITF
R
el
at
iv
e 
ra
tio
 o
f 
Ty
ro
sin
as
e/
ac
tinPDZK1 siRNAControl siRNA
PDZK1 siRNAControl siRNA
PDZK1Control
Control
e
PDZK1Control
c
C PDZK1 C PDZK1
NC
KC+MC MC
1.5
oligo1 oligo2 oligo1+2
Fold
Fold
ER-α
ER-β
ER-α
ER-β2.5
R
at
io
s 
of
 in
cr
em
en
t Fold
R
at
io
s 
of
 in
cr
em
en
t
d
a
# #
(nM)
0 10 1000 10 100 (nM)
2
1
0
1
0.5
0
2
1.5
1
0.5
0
PDZK1
KC+MC
PDZK1
MC
Patients
Tyrosinase
PDZK1
β-Actin
β-Actin
β-Actin
β-Actin
β-Actin
Estrogen 0 10 100 (nM)
0 10 1000 10 100
Tyrosinase
PDZK1
Estrogen
2
1.5
1
0.5
0
* *
*
*
# #
Tyrosinase
PdZK1
ER-α
ER-β
66 kDa
56 kDa
Estrogen
ER-α
ER-β
β-Actin
3
2.5
2
1.5
1
0.5
0
*
*
*
*
## # #
0 10 1000 10 100
Control siRNA siRNAPDZK1
(nM)
PDZK1
ER-α
ER-β10
R
at
io
s 
of
 in
cr
em
en
t 9
8
7
6
5
4
3
2
1
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14
*
*
*
*
Figure 2. PDZK1 affects estrogen-induced tyrosinase expression. (a, b) Western blotting of PDZ domain protein kidney 1 (PDZK1) or tyrosinase expression after
treatment of indicated concentrations of estrogen only or with PDZK1 overexpression or knockdown. (c, d) Western blotting of estrogen receptor (ER)-a and
ER-b in total cell lysates, prepared 24hours after PDZK1overexpression, or estrogen with or without PDZK1 knockdown. Data in the graphs (b–d) represent
means±SD of five independent experiments (*Po0.05 vs. untreated control, #Po0.05 vs. samples treated with the corresponding concentration of estrogen).
(e) Real-time PCR of ER-a and ER-b in the hyperpigmented compared with normally pigmented skin from 14 of the 15 patients. ERK, extracellular
signal–regulated kinase; KC, keratinocytes; MC, melanocytes; MITF, microphthalmia-associated transcription factor; siRNA, small interfering RNA.
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in vitro system in this study using keratinocyte–melanocyte
cocultures and melanocyte monocultures. Increased expres-
sion of tyrosinase (Figure 1d), as well as of tyrosinase
transcription regulator, microphthalmia-associated transcrip-
tion factor, and stimulation of extracellular signal–regulated
kinase, CRE-binding protein, and protein kinase C phos-
phorylation with the PDZK1 upregulation (Figure 1e)
suggested a role of these pathways in tyrosinase and
microphthalmia-associated transcription factor upregulation.
Estrogen stimulates PDZK1 expression in ER-containing
cells (Ediger et al., 1999; Stemmer-Rachamimov et al., 2001);
however, the estrogen-induced upregulation of PDZK1 has
not been reported in connection with melanogenesis. In this
study, we showed that estrogen-stimulated expression of
PDZK1 paralleled tyrosinase expression (Figure 2a), although
PDZK1 overexpression did not change the cell number either
in melanocytes or keratinocytes (data not shown). The
estrogen-induced tyrosinase expression was increased further
by PDZK1 overexpression and was inhibited by the knock-
down of PDZK1 (Figure 2b), which suggests that estrogen is
involved in regulating melanogenesis through PDZK1. It
could be expected that the action of estrogen would intensify
in the skin with upregulated PDZK1, even though serum
estrogen levels were the same. Of course, it does not mean
that innate pigmentation is linked to estrogen. If it did, young
women would tend to be darker as they ascend through
puberty and men would have fairer skin compared with
women. The result that overexpression of PDZK1 (Figure 2c),
as well as estrogen treatment (Figure 2d), increased the
expression of both ER-a and ER-b, whereas knockdown of
PDZK1 reduced the estrogen-induced upregulation of ERs
down to the untreated control levels (Figure 2d) indicated the
function of estrogen induced through the expression of its
receptors (Katzenellenbogen et al., 2000). ER expression in
patients with PDZK1-upregulated melasma (Figure 2e)
supported the potential association between PDZK1 and
ERs, although the expression levels between PDZK1 and ER-a
and/or ER-b were not correlated in some patients. It is unclear
why the levels were not correlated. Other types of ERs
(GPER1/GPR30 (Nilsson et al., 2011)) or other factors (anti-
estrogens, protein kinase activators, and growth factors) may
be involved in the regulation of ER biological activity
(Katzenellenbogen, 1996). The increase in ER expression in
concert with PDZK1 overexpression in cultured cells (data
not shown) further supported the fact that PDZK1 regulated
ER expression.
NHERF family proteins mediate the most abundant
protein–protein interactions and bind to NHE, CFTR, and
the SLC26A family. Although no report has been available
about the interaction, western blotting analysis (Figure 3a)
and immunoprecipitation with and without PDZK1 over-
expression (Figure 3b) revealed that three transporter proteins
(CFTR, NHE3, and SLC26A3) interacted with PDZK1 in
epidermal keratinocytes and melanocytes as they do in other
organs (Gisler et al., 2003; Rossmann et al., 2005). In
addition, double staining in cultured cells with and without
PDZK1 overexpression showed the interactions and coloca-
lization between transporter proteins and PDZK1 (data not
shown except CFTR in Figure 3c). Estrogen also acted on the
expression of three transporter proteins (Figure 4a) similar to
that of PDZK1 (Figure 2a), although each specific inhibitor of
those transporter proteins inhibited the estrogen-induced
expression of tyrosinase in the presence or absence of PDZK1
overexpression without a change in the expression of PDZK1
(Figure 4b and c), which indicates that the transporter
proteins are downstream of PDZK1 in the signaling pathway
of estrogen-induced expression of tyrosinase. The role of ion
transporters in the estrogen-induced expression of tyrosinase
is further supported by the results of ER agonist treatment; the
ER-a agonist increased NHE3 expression and the ER-b agonist
changed CFTR. As the ER-a agonist did not induce a
significant change in CFTR and the ER-b agonist did not
affect NHE3 expression (Figure 4d), there seems to be a
specific association between each ER subtype and an ion
transporter. In fact, the expression of NHE3 is reduced in ER-
a-knockout mice (Lee et al., 2001; Zhou et al., 2001),
whereas CFTR expression is increased (Lee et al., 2001). As
estrogen exerts its actions through ER-b in ER-a-knockout
mice (Shughrue et al., 1997), the modulation of CFTR
expression through ER-b could be explained. Interestingly,
concordance in the expression between ion transporter and
each ER subtype, particularly between CFTR and ER-b, was
suggested in a patient with melasma (Figure 4e).
In addition to melanogenesis, the FACS analysis results
showed that PDZK1 upregulation stimulated melanosome
transfer to keratinocytes. With the reduction of PDZK1-
induced melanosome transfer by inhibitors of ERs and by ion
transporter (Figure 5a), sequential processes of estrogen
through PDZK1 and then ERs into ion transporters could be
suggested for PDZK1-induced melanosome transfer. Whereas
PAR-2 is involved in melanosome transfer (Seiberg et al.,
2000), Rac1 and ERM instead of PAR-2 are involved in
PDZK1-stimulated melanosome transfer (Figure 5b).
In summary, this study demonstrates a significant role for
the upregulation of PDZK1 in the development of hyperpig-
mentation in the skin of melasma patients, particularly
associated with estrogen, through identification of the clinical
correlation and the mechanism of action with its interacting
Figure 3. PDZK1 over-expression upregulates NHE, CFTR, and SLC26A3. (a) Western blot analysis of NHE1, NHE3, CFTR, and SLC26A3 expression in
melanocytes and cocultures (KCþMC) 24 hours after transfection of PDZ domain protein kidney 1 (PDZK1). Data in the graphs represent means±SD of five
independent experiments (*Po0.05). (b) Immunoprecipitation (IP) of total cell lysates of melanocytes and keratinocytes using an anti-PDZK1 antibody with or
without PDZK1overexpression, followed by reactivity with antibodies as noted. (c) Immunohistochemical staining of cells with or without PDZK1overexpression
using anti-PDZK1 and anti-CFTR antibodies. Nuclei were counterstained with Hoechst 33258 (bar¼0.1mm). CFTR, cystic fibrosis transmembrane conductance
regulator; ERK, extracellular signal–regulated kinase; KC, keratinocytes; MC, melanocytes; MITF, microphthalmia-associated transcription factor; NHE1,
sodium–hydrogen exchanger 1.
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Figure 4. NHE3, CFTR, and SLC26A3 involvement in estrogen-induced tyrosinase expression. (a) Western blotting of NHE3, CFTR, and SLC26A3 expression
after indicated concentrations of estrogen (ES) treatment. (b, c) Western blotting of tyrosinase and NHE3 or CFTR expression after treatment of 100nM estrogen
with or without a specific inhibitor of NHE3 (5-ethylisopropyl amiloride, EIPA), or CFTR (172Inh) with or without PDZ domain protein kidney 1 (PDZK1)
overexpression (*Po0.05 vs. untreated control, #Po0.05 vs. samples treated with the corresponding concentration of estrogen). (d) Western blotting after indicated
concentrations of specific agonists of ER-a (propyl pyrazoletriol, PPT) or ER-b (diarylpropionitrile, DPN) (*Po0.05). Data in the graphs (b–d) represent means±SD of
five independent experiments. (e) Real-time PCR analysis of the association of ER-a with NHE3 mRNA expression and of ER-b with CFTR expression in 12 melasma
skin samples with PDZK1 upregulation. (Line indicates expression level of each molecule in normal skin.) CFTR, cystic fibrosis transmembrane conductance
regulator; ER, estrogen receptor; ERK, extracellular signal–regulated kinase; KC, keratinocytes; MC, melanocytes; NHE3, sodium–hydrogen exchanger 3.
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molecules. These results indicate the potential application of
PDZK1 and/or ion transporters for the targeted therapy in
melasma.
MATERIALS AND METHODS
Patients
Fifteen female patients diagnosed with melasma (36 to 61 years, with
a mean age of 48 years) were included in the study. The Institutional
Review Board of the Dongguk University Ilsan Hospital approved
this study, and the study was conducted according to the
Declaration of Helsinki Principles. After obtaining informed written
consent from each patient, pairs of normally pigmented and
hyperpigmented skin specimens were taken by biopsy for direct
comparisons. The locations of the hyperpigmented lesions were the
forehead or upper cheeks, which were shaded by scalp hairs.
Control uninvolved skin was taken from the retroauricular area.
These specimens were used for real-time PCR and immunohisto-
chemistry.
Normal human epidermal cell culture
Skin specimens obtained from cesarean sections and circumcisions
were used for establishing cells in culture. The epidermis was
separated from the dermis, and suspensions of individual epidermal
cells were prepared.
Keratinocytes were suspended in EpiLife medium (#M-EPI-500-
CA; Invitrogen, Carlsbad, CA) supplemented with bovine pituitary
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Figure 5. PDZK1 and ion transporter are involved in estrogen-induced melanosome transfer with ezrin/radixin/moesin (ERM) and Rac1 phosphorylation.
(a) FACS analysis using anti-TYRP-1 and anti-K14 antibodies in cocultures. Both melanocytes and keratinocytes, which were transfected with or without
PDZ domain protein kidney 1 (PDZK1), were treated with inhibitor of both estrogen receptor (ER)-a and ER-b (ICI), inhibitor of ER-b (PHTPP), or a specific
inhibitor of NHE3 (5-ethylisopropyl amiloride, EIPA) or CFTR (172Inh) (*Po0.05 vs. untreated control, #Po0.05 vs. samples with overexpression of PDZK1).
(b) Western blot assays of ERM and Rac1 phosphorylation and PAR-2 expression in the cocultures with or without PDZK1 overexpression (*Po0.05). Data in the
graphs represent means±SD of five independent experiments. CFTR, cystic fibrosis transmembrane conductance regulator; ER, estrogen receptor; ERK,
extracellular signal–regulated kinase; NHE3, sodium–hydrogen exchanger 3; PAR-2, proteinase-activated receptor 2; Rac1, ras-related C3 botulinum toxin
substrate 1.
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extract, bovine insulin, hydrocortisone, human epidermal growth
factor, and bovine transferrin (#S-001-5; Invitrogen). Keratinocytes
from passages 3 or 4 were used in these experiments. Melanocytes
were suspended in Medium 254 (Invitrogen) supplemented with
bovine pituitary extract, fetal bovine serum, bovine insulin,
hydrocortisone, basic fibroblast growth factor, bovine trans-
ferrin, heparin, and phorbol 12-myristate 13-acetate (Invitrogen).
Melanocytes at passage numbers between 7 and 15 were used for
these experiments.
All procedures were performed three times for each of the three
cell lines, i.e., a total of nine procedures for each experiment.
PDZK1 overexpression and knockdown
For PDZK1 overexpression, transfection of cells with pcDNA3.1-
MYC containing the PDKZ1 gene was carried out using Lipofecta-
mine 2000 according to the manufacturer’s protocol. For PDZK1
downregulation, cultured cells in six-well plates were transfected
with two different stealth small interfering RNAs (1, 2) and a negative
control stealth small interfering RNA (Invitrogen) using Lipofecta-
mine LTX (Invitrogen) and 60 nM small interfering RNA, according to
the manufacturer’s instructions. The cells were used for the
experiments 48 hours after the transfection.
Treatment with estrogen with or without specific inhibitors
against ion transporters, ER agonists, or ER antagonists
The transfected cells were incubated for 24 hours in media contain-
ing 10 nM or 100 nM 17b-Estradiol (E2), with or without 5mM CFTR
172Inh (a CFTR inhibitor), and 5mM 5-ethylisopropyl amiloride (a
NHE inhibitor; Sigma Diagnostics, St Louis, MO).
The cultured cells were incubated in media without supplements,
after which they were treated with 10 nM or 100 nM propyl
pyrazoletriol (an ER-aagonist), 100 nM or 1,000 nM diarylpropionitrile
(an ER-b agonist; Tocris Bioscience, Ellisville, MO), 1 mM PHTPP (an
ER-b antagonist), or 2.5 mM ICI 182,780 (an ER-a,b antagonist; Sigma
Diagnostics) for 24 hours.
Reverse transcription–PCR
Total RNAs from cells cultured under each condition were obtained
with TrizolReagent (Invitrogen). Reverse transcription of each RNA
was performed using a First Strand cDNA Synthesis Kit for RT-PCR
(AMV; Boehringer, Mannheim, Germany). Human glyceraldehyde
3-phosphate dehydrogenase was used as the internal standard. The
primer sequences for PDZK1 were as follows: forward 50-ATGA
CCTCCACCTTCAACCCC-30 and reverse 50-ACATCTCTGTATCT
TCAGAAT-30. The primer sequences for glyceraldehyde 3-phosphate
dehydrogenase were as follows: forward 50-TCCACTGGC-GTC
TTCACC-30 and reverse 50-GGCAGAGATGATGACCCTTTT-30. The
DNA fragments produced by PCR were separated by electrophoresis
on 2% agarose gels.
Real-time PCR
Levels of mRNAs relative to glyceraldehyde 3-phosphate dehydro-
genase were measured by quantitative real-time PCR using the Light
Cycler real-time PCR (Roche, Mannheim, Germany). The primers
used were as follows: PDZK1 50-GGCAGGCTCAGAACAGAAAG-30
(forward) and 50-CTACCAGATCATTGTTCTTC-30 (reverse); ER-a50-
TGTGCAATGACTATGCTTCA-30 (forward) and 50-GCTCTTCCTC
CTGTTTTTA-30 (reverse); ER-b50-GTATGCGGAACCTCAAAAGA
G-30 (forward) and 50-GTTCCCACTAACCTTCCTTTTC-30 (reverse);
NHE350-GGAGTCCTTCAAGTCGACCA-30 (forward) and 50-GGGA
TGCTGCTGTTTCTCC-30 (reverse); CFTR 50-GAAGTAGTGATGG
AGAATGTAACAGC-30 (forward) and 50-GCTTTCTCAAATAATTCC
CCAAA-30 (reverse); and glyceraldehyde 3-phosphate dehydrogen-
ase 50-TCCACTGGCGTCTTCACC-30 (forward) and 50-GGCAGAGA
TGATGACCCTTT-30 (reverse).
Western blot analysis
Equal amounts of extracted proteins (20 mg) were resolved using 10%
SDS-PAGE and were then transferred to nitrocellulose membranes.
The membranes were incubated with antibodies to phospho-
extracellular signal–regulated kinase, extracellular signal–regulated
kinase, phospho-CRE-binding protein, CRE-binding protein, phos-
pho-protein kinase C, protein kinase C, phospho-ERM, ERM,
phospho-Rac1, Rac1 (rabbit polyclonal; Cell Signaling Technology,
Beverly, MA), tyrosinase, SLC26A3 (goat polyclonal; Santa Cruz
Biotechnology, Santa Cruz, CA), ER-a, ER-b, NHE3, CFTR, micro-
phthalmia-associated transcription factor (rabbit polyclonal; Santa
Cruz Biotechnology), PDZK1 (mouse monoclonal; Santa Cruz
Biotechnology), and further with anti-rabbit or anti-mouse horse-
radish peroxidase–conjugated antibodies (Santa Cruz Biotechnol-
ogy), and were then treated with an enhanced chemiluminescence
solution (Thermo, Rockford, IL). The signals were captured on an
Image Reader (LAS-3000; Fuji Photo Film, Tokyo, Japan). To monitor
the amount of protein loaded in each lane, the membranes were
reprobed with mouse monoclonal anti-b-actin antibody (Sigma) and
were processed as described above. Protein bands were analyzed by
densitometry.
Immunohistochemistry
For immunofluorescence staining, after deparaffinization and
rehydration, the sections were preincubated with 3% BSA. For
double staining, the cultured cells or sections were reacted sequen-
tially with the anti-PDZK1 antibody and 1:200 Alexa Fluor–labeled
goat anti-mouse IgG (488; Molecular Probes, Eugene, OR), and then
with anti-c-kit, ER-a, ER-b, and CFTR antibodies and Alexa
Fluor–labeled goat anti-rabbit IgG (594; Molecular Probes). Nuclei
were counterstained with Hoechst 33258 (Sigma). The stained
specimens were evaluated using an image analysis system (Dp
Manager 2.1; Olympus Optical, Tokyo, Japan).
Immunoprecipitation
Cells were solubilized with lysis buffer and centrifuged at 10,000g
for 10minutes at 4 1C. Lysates were immunoprecipitated with the
anti-PDZK1 antibody, and were then separated by SDS-PAGE.
Western blotting was performed using antibodies against CFTR,
NHE1, NHE3, and SLC26A3.
Melanosome transfer
Flow cytometry was used for quantitative analysis of melano-
some transfer to keratinocytes, as previously described (Lin et al.,
2008). In brief, the cells were fixed with 2% paraformaldehyde for
10minutes, washed with phosphate-buffered saline containing BD
PhosFlow Perm/Wash Buffer I (BD Biosciences, San Jose, CA) for
10minutes, and then incubated with both FITC-conjugated goat anti-
TYRP-1 (1 g per 1 106 cells; Santa Cruz Biotechnology) and
phycoerythrin-conjugated mouse anti-Cytokeratin 14 (1:10; BD
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Biosciences) for 30minutes at room temperature. The cells were
then washed thoroughly with phosphate-buffered saline and
prepared for flow cytometry. Labeled cells were analyzed with a
Cytomics FC500 flow cytometer (Beckman Coulter, Hialeah, FL)
using the CXP software (Beckman Coulter). The melanosome transfer
efficacy was determined as the number of Cytokeratin 14–positive
and TYRP-1-positive cells divided by the total number of Cytokeratin
14–positive cells.
Statistical analysis
Statistical significance was evaluated using one-way analysis of
variance analysis with the Bonferroni’s multiple comparison test.
The Wilcoxon signed rank test was used to analyze statistical
significance between hyperpigmented and normally pigmented skin
specimens. A P-value of less than 0.05 is considered to be
statistically significant. All results are presented as means±SD of
the combined data from replicate experiments.
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